Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Grace Therapeutics Inc (GRCE)

Grace Therapeutics Inc (GRCE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 71,026
  • Shares Outstanding, K 15,474
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,570 K
  • EBIT $ -11 M
  • EBITDA $ -11 M
  • 60-Month Beta 0.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.10

Options Overview Details

View History
  • Implied Volatility 438.62% (+22.41%)
  • Historical Volatility 108.02%
  • IV Percentile 67%
  • IV Rank 53.76%
  • IV High 769.94% on 03/11/26
  • IV Low 53.34% on 01/26/26
  • Expected Move (DTE 24) 3.61 (77.52%)
  • Put/Call Vol Ratio 0.69
  • Today's Volume 1,947
  • Volume Avg (30-Day) 1,299
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 16,062
  • Open Int (30-Day) 7,849
  • Expected Range 1.05 to 8.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.24
  • Number of Estimates 1
  • High Estimate $-0.24
  • Low Estimate $-0.24
  • Prior Year $-0.21
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.50 +86.40%
on 04/07/26
5.18 -10.04%
on 04/02/26
+0.24 (+5.43%)
since 03/20/26
3-Month
2.50 +86.40%
on 04/07/26
5.18 -10.04%
on 04/02/26
+0.99 (+26.98%)
since 01/21/26
52-Week
2.15 +116.74%
on 04/22/25
5.18 -10.04%
on 04/02/26
+2.51 (+116.74%)
since 04/21/25

Most Recent Stories

More News
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel,...

GRCE : 4.66 (+1.53%)
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences

PRINCETON, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel,...

GRCE : 4.66 (+1.53%)
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

PRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel,...

GRCE : 4.66 (+1.53%)
Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON...

GRCE : 4.66 (+1.53%)
Grace: Fiscal Q3 Earnings Snapshot

Grace: Fiscal Q3 Earnings Snapshot

GRCE : 4.66 (+1.53%)
Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference

PRINCETON, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel,...

GRCE : 4.66 (+1.53%)
Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

Announced U.S. Food and Drug Administration (FDA) Acceptance for Review of New Drug Application (NDA) for GTx-104 FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking...

GRCE : 4.66 (+1.53%)
Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting

PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel,...

GRCE : 4.66 (+1.53%)
Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel,...

GRCE : 4.66 (+1.53%)
Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel,...

GRCE : 4.66 (+1.53%)

Business Summary

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton,...

See More

Key Turning Points

3rd Resistance Point 5.49
2nd Resistance Point 5.28
1st Resistance Point 4.93
Last Price 4.66
1st Support Level 4.37
2nd Support Level 4.16
3rd Support Level 3.81

See More

52-Week High 5.18
Last Price 4.66
Fibonacci 61.8% 4.02
Fibonacci 50% 3.66
Fibonacci 38.2% 3.31
52-Week Low 2.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.